Silco Pharmaceuticals Limited
Nature of business
|
Silco Pharmaceuticals limited has engaged in manufacturing and marketing of pharmaceuticals finished product in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Antipyretics, Anti Inflammatory Drugs, Antiulcer ants, Multi medicines which are sold in local market.It has set up a modern pharmaceutical plant that is equipped with advanced and modern machineries and technologies.
|
Reason for IPO
|
Construction of new factory building in the existing vacant area144,655,552 (48.22%)Import of new Machinery97,356,000.00 (32.45%)Purchase of Delivery Van36,310,000.00 (12.10%)IPO Expenses21,678,448.00 (7.23%)Total300,000,000 (100.00%)
|
Subscription open
|
07 Mar 0201
|
Subscription close
|
19 Mar 2019
|
Subscription close for NRB
|
07 Mar 0201
to 19 Mar 2019
|
Offer price
|
Tk. 10.0
|
Face value per share
|
Tk. 10.0
|
Market lot
|
500 units
|
Single lot price
|
Tk. 5000.0
|
EPS
|
Tk. 1.64for the period ended on June 30, 2018
|
NAV
|
Tk. 27.05as on June 30, 2018
|
Public offer
|
|
Major product
|
The Company has following principal products:1.Tablet; 2. Capsules; 3. Liquid Syrup; 4. Dry Syrup; 5. Pellet; 6. Powder; 7.Powder Suspension; 8. SRS Saline
|
Issue Manager
|
EBL Investments Limited, City Bank Capital Resources Limited&Citizen Securities & Investment Limited
|
Website
|
http://www.silcopharma.com/
|